Frontlight ResearchEarly access
CompletedNo phase
Supplemental Thiamine in Septic Shock: A Before-after Study
Key facts
- Who runs it
- Hospital Sao Domingos
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 73 people enrolled
- Started
- 1 Sept 2023
- Ended
- 31 Dec 2023
- Type of study
- Observational, 2 groups
- Treatments tested
- Thiamin
- Record updated
- 18 April 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- age > 18 years
- presence of documented or suspected infection, SOFA score ≥ 2, serum lactate levels > 18 mg/dL and hypotension, MAP < 65 mm Hg maintained after volume expansion of at least 30 ml/kg in the first 2 hours of treatment followed by noradrenaline vasopressor dependence (with or without vasopressin) during the first 6 hours of treatment
Who cannot take part
- pregnant women
- patients treated only with comfort measures
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This controlled before-and-after study analyse the impact of thiamine supplementation on outcomes of patients with septic shock treated according to the surviving sepsis campaign 2021 guidelines
The 2 groups in the trial
- Control group
Septic shock patients treated according surviving sepsis campaign 2021 guidelines
- Intervention group
Septic shock patients treated according surviving sepsis campaign 2021 guidelines supplemented with thiamin 200 mg in 50 ml 5% dextrose twice daily for 7 days.
Treatment: Thiamin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Thiamine Supplementation on Clinical Outcomes of Patients With Septic Shock: a Retrospective Before-after Study
- Record updated
- 18 April 2024